Weight loss induced by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual
glucagon‐like peptide‐1 receptor (GLP‐1R)/glucose‐dependent insulinotropic polypeptide …

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1
receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes …

Background Facioscapulohumeral muscular dystrophy is a hereditary progressive myopathy
caused by aberrant expression of the transcription factor DUX4 in skeletal muscle. No …

Background It is unclear how changes in quantitative muscle magnetic resonance imaging
(MRI) relate to changes in clinical outcome in facioscapulohumeral muscular dystrophy …

The FSHD jigsaw: are we placing the tiles in the right posit... : Current Opinion in Neurology
The FSHD jigsaw: are we placing the tiles in the right position? : Current Opinion in Neurology …

Objective With potential therapies for many forms of Charcot‐Marie‐Tooth disease (CMT),
responsive outcome measures are urgently needed for clinical trials. Quantitative lower limb …

Facioscapulohumeral muscular dystrophy (FSHD) affects roughly 1 in 7500 individuals.
While at the population level there is a general pattern of affected muscles, there is …

Facioscapulohumeral muscular dystrophy (FSHD) represents the third most common form of
muscular dystrophy and is characterized by muscle weakness and atrophy. FSHD is caused …

On 22–24 April 2022 the 265th ENMC International Workshop on “Muscle Imaging in
Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials” took place as …

Abstract Introduction/Aims Ultrasound imaging of muscle tissue conventionally results in two‐
dimensional sampling of tissue. For heterogeneously affected muscles, a sampling error …